镥[177Lu]DOTATATE 治疗骨转移病例的一种新放射性药物 225Ac-DOTA-IBA。
A New Radiopharmaceutical 225 Ac-DOTA-IBA in the Treatment of a Case of Bone Metastases.
机构信息
From the Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University; Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province; and Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, People's Republic of China.
出版信息
Clin Nucl Med. 2023 Jul 1;48(7):650-652. doi: 10.1097/RLU.0000000000004688. Epub 2023 May 11.
α-Emitter 225 Ac has been considered a candidate for targeted α-therapy. DOTA-IBA is new a precursor targeting bone metastasis. It can be used for radionuclide labeling with 225 Ac. We present a case with refractory bone pain for bone metastasis, who demonstrated an excellent therapy response after 1 cycle of 225 Ac-DOTA-IBA therapy. Moreover, the patient did not have any observable adverse effects.
α-发射体 225 Ac 已被认为是靶向 α 治疗的候选物。DOTA-IBA 是一种新的针对骨转移的前体药物。它可以用于 225 Ac 的放射性核素标记。我们报告了 1 例因骨转移导致难治性骨痛的患者，在接受 1 周期 225 Ac-DOTA-IBA 治疗后，显示出极好的治疗反应。此外，患者没有任何明显的不良反应。
Zotero 插件